Vedanta Biosciences Inc. has begun a phase Ia/Ib trial of VE-303, its oral immune-modulating bacterial consortia therapy. Study of the medicine, derived from the human microbiome, is expected to finish up in the first half of 2018. If all goes well, the company plans to initiate a phase II trial in 2018 for the treatment of recurrent Clostridium difficile infection (rCDI).